Breaking News Instant updates and real-time market news.

BBIO

BridgeBio

$34.53

0.96 (2.86%)

, DAC

Danaos

$9.13

0.18 (2.01%)

08:30
01/15/20
01/15
08:30
01/15/20
08:30

Five new option listings and one option delisting on January 15th

New option listings for January 15th include BridgeBio Pharma Inc (BBIO), Danaos (DAC), Diamond Eagle Acquisition Corp (Class A Stock) (DEAC), Karuna Therapeutics Inc (KRTX), and Cassava Sciences Inc (SAVA). Option delistings effective January 15th include SRC Energy Inc (SRCI).

BBIO

BridgeBio

$34.53

0.96 (2.86%)

DAC

Danaos

$9.13

0.18 (2.01%)

DEAC

Diamond Eagle Acquisition

$11.90

-0.1 (-0.83%)

KRTX

Karuna Therapeutics

$85.10

10.83 (14.58%)

SAVA

Cassava Sciences

$7.40

0.42 (6.02%)

SRCI

SRC Energy

$3.98

-0.1 (-2.45%)

  • 15

    Jan

  • 16

    Jan

BBIO BridgeBio
$34.53

0.96 (2.86%)

11/19/19
PIPR
11/19/19
NO CHANGE
Target $75
PIPR
Overweight
Eidos Therapeutics price target raised to $75 from $55 at Piper Jaffray
Piper Jaffray analyst Tyler Van Buren raised his price target for Eidos Therapeutics to $75 from $55 and reiterates an Overweight rating on the shares following the initial AG10 long-term outcomes data. The stock closed Monday up 18% to $55.02. After speaking with a key opinion leader, the analyst believes that BridgeBio (BBIO) and Eidos's AG10 appears superior to the anticipated blockbuster Vyndaqel/tafamidis. Van Buren says he's using a "conservative" one-times multiple on a 2030 AG10 sales estimate. He believes the ATTR cardiomyopathy market could grow to an eventual $5B-$10B opportunity as the pool of diagnosed patients expands several-fold. In addition, the new price target does not include a premium for a takeout, which is more likely following the AG10 data, Van Buren tells investors in a research note.
01/07/20
RAJA
01/07/20
NO CHANGE
Target $40
RAJA
Outperform
BridgeBio price target raised to $40 from $36 at Raymond James
Raymond James analyst Dane Leone raised his price target for BridgeBio to $40 from $36 after its QED subsidiary announced that infigratinib had received Fast Track Designation for treatment of 1st line advanced or metastatic cholangiocarcinoma, along with an update on the pivotal PROOF study. Leone tells investors in a research note that he thinks that the premium multiple relative to the mid cap biotech peer group multiple is warranted, given the breadth of programs and current clinical datasets.
10/18/19
PIPR
10/18/19
NO CHANGE
Target $50
PIPR
Overweight
BridgeBio has 'best-in-class' potential in achondroplasia, says Piper Jaffray
Piper Jaffray analyst Tyler Van Buren reiterates an Overweight rating on BridgeBio with a $50 price target after new preclinical data for infigratinib in achondroplasia were presented. The drug is effective at lower and less frequent dosing regimens than previously tested, says the analyst, who believes infigratinib could capture 50% achondroplasia market share by 2035, which could amount to over $1.5B in sales. He sees "best-in-class potential" for the drug.
09/13/19
BTIG
09/13/19
NO CHANGE
Target $56
BTIG
Buy
Eidos Therapeutics price target raised to $56 from $38 at BTIG
BTIG analyst Thomas Shrader raised his price target on Eidos Therapeutics (EIDX) to $56 and kept his Buy rating after the decision by its board to reject an acquisition offer from parent company BridgeBio (BBIO) to buy all of its outstanding stock. The analyst notes that he always believed the combined entity would not be a more attractive investment, saying he is positive on the company's "declaration of independence". Shrader further cites the added revenue contribution expected from Eidos Therapeutics' deal with Alexion (ALXN) to develop and commercialize AG10 in Japan.
DAC Danaos
$9.13

0.18 (2.01%)

12/03/19
12/03/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Wingstop (WING) upgraded to Buy from Neutral at BTIG with analyst Peter Saleh saying he is positive on the company's strong concept fundamentals and looks ahead to its inaugural investment day for some "eventful developments" that may include the unveiling of new kitchen equipment that materially reduces chicken wing cook times. 2. Boston Beer (SAM) upgraded to Buy from Neutral at UBS with analyst Sean King saying he expects continued double-digit sales and earnings growth from Boston Beer in fiscal 2020 and 2021 and sees upside to 2020 shipment and depletion guidance. 3. Aptiv (APTV) upgraded to Overweight from Neutral at Piper Jaffray with analyst Alexander Potter saying relative to "plain vanilla" auto suppliers, Aptiv's growth profile has "inarguably sheltered" the company from weakening auto production. 4. Danaos (DAC) upgraded to Buy from Hold at Jefferies with analyst Randy Giveans saying Danaos recently completed a secondary offering of 9M shares, which removes an overhang. 5. Ranger Energy (RNGR) upgraded to Outperform from Neutral at Credit Suisse with analyst Jacob Lundberg saying the company's high spec service rig business looks set to outperform the service market. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/03/19
JEFF
12/03/19
UPGRADE
Target $9
JEFF
Buy
Danaos upgraded to Buy from Hold at Jefferies
Jefferies analyst Randy Giveans upgraded Danaos to Buy from Hold with a $9 price target.
12/03/19
JEFF
12/03/19
UPGRADE
Target $9
JEFF
Buy
Jefferies upgrades Danaos to Buy with equity raise overhang removed
Jefferies analyst Randy Giveans upgraded Danaos to Buy from Hold with a price target of $9, down from $11. Danaos recently completed a secondary offering of 9M shares, which removes an overhang, Giveans tells investors in a research note. He believes the shares are undervalued and should soon reflect the company's "strong" balance sheet, "substantial" charter backlog, and likely dividend payment in 2020.
DEAC Diamond Eagle Acquisition
$11.90

-0.1 (-0.83%)

12/24/19
MSCO
12/24/19
NO CHANGE
MSCO
Morgan Stanley sees positive read to Boyd and peers from DraftKings' valuation
After DraftKings announced yesterday that it is being bought by Special Purpose Acquisition Company Diamond Eagle (DEAC) and merging with SBTech in a deal that values the combined U.S. sports betting pure play company at an enterprise value of $2.7B, Morgan Stanley analyst Thomas Allen said he sees this new valuation as having a positive read-through for Boyd Gaming (BYD), Eldorado Resorts (ERI) and Penn National (PENN), which he thinks are likely to also be meaningful long-term beneficiaries from U.S. sports betting. He also sees the read-through being positive for MGM Resorts (MGM) and Wynn Resorts (WYNN), though to a lesser extent given the scale of those two.
KRTX Karuna Therapeutics
$85.10

10.83 (14.58%)

01/09/20
JMPS
01/09/20
INITIATION
Target $122
JMPS
Outperform
Karuna Therapeutics initiated with an Outperform at JMP Securities
JMP Securities analyst Jason Butler initiated coverage of Karuna Therapeutics with an Outperform rating and $122 price target, citing his view that Karuna's lead candidate KarXT can be "a truly novel and differentiated" treatment for schizophrenia and other neuropsychiatric disorders. Previously reported Phase 2 results for KarXT in schizophrenia were "very strong" and he expects KarXT to advance into later-stage development is dementia-related psychoses next, Butler tells investors.
12/19/19
STFL
12/19/19
INITIATION
Target $126
STFL
Buy
Karuna Therapeutics initiated with a Buy at Stifel
Stifel analyst Paul Matteis initiated coverage of Karuna Therapeutics with a Buy rating and $126 price target. The analyst sees blockbuster potential of KarXT, a muscarinic receptor agonist under study for the treatment of psychosis. The KarXT schizophrenia efficacy data "are about as strong as one could realistically hope" for a Phase 2, Matteis tells investors in a research note. Whether this will hold up in Alzheimer's remains an open question, but schizophrenia alone justifies "meaningful upside" for Karuna shares, says the analyst.
12/12/19
WBLR
12/12/19
INITIATION
WBLR
Outperform
Karuna Therapeutics initiated with an Outperform at William Blair
William Blair analyst Myles Minter initiated coverage of Karuna Therapeutics with an Outperform rating.
01/14/20
WBLR
01/14/20
NO CHANGE
WBLR
Karuna Therapeutics' KarXT surpasses expectations, says William Blair
William Blair analyst Myles Minter maintained an Outperform rating and $105 price target on Karuna Therapeutics after the company disclosed the effect size from its positive Phase II trial of KarXT for the treatment of schizophrenia, which surpassed the analyst's expectations and "exemplifies the therapy's best-in-class risk/benefit profile." Minter called it "the first truly novel antipsychotic in over 30 years that possesses efficacy in the range of the atypical antipsychotics without the compliance-restricting adverse effects triggered by dopamine receptor antagonism." In afternoon trading, shares of Karuna are higher by 17.1% to $86.84.
SAVA Cassava Sciences
$7.40

0.42 (6.02%)

08/01/19
HCWC
08/01/19
INITIATION
Target $3
HCWC
Buy
Cassava Sciences initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Vernon Bernardino started Cassava Sciences with a Buy rating and $3 price target. The analyst sees "unique" disease-modifying potential of PTI-125, the company's Phase 2 stage drug candidate for Alzheimer's disease., saying it demonstrates potential to restore dysfunctional brain cell signaling. Further, Cassava's strategic shift away from its analgesic drug development programs in Q1 removed an overhang from the legacy of Remoxy's failure to advance into commercialization, Bernardino contends.
01/10/20
MAXM
01/10/20
NO CHANGE
Target $12
MAXM
Buy
Cassava Sciences price target raised to $12 from $3 at Maxim
Maxim analyst Jason McCarthy raised his price target on Cassava Sciences shares to $12 from $3, stating that he expects shares could continue to rise in value through 2020 as activity in the Alzheimer's disease space continues to heat up. He believes insider buying, the Phase 2a data, and expectations around Cassava's Phase 2b trial in 2020 have all played a hand in the stock's significant rise in value since mid-December, added McCarthy, who keeps a Buy rating on the stock.
08/01/19
08/01/19
INITIATION

Fly Intel: Top analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. AMD (AMD) and Maxim Integrated (MXIM) initiated with a Hold at Benchmark. 2. Amag Pharmaceuticals (AMAG) and Cassava Sciences (SAVA) initiated with a Buy at H.C. Wainwright. 3. Crispr Therapeutics (CRSP) initiated with a Buy at Jefferies. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/06/19
HCWC
12/06/19
NO CHANGE
Target $6
HCWC
Buy
Cassava Sciences price target raised to $6 from $3 at H.C. Wainwright
H.C. Wainwright analyst Vernon Bernardino raised his price target on Cassava Sciences to $6 from $3 and reiterated his Buy rating on the stock following the company's presentation of data at the Clinical Trials on Alzheimer's Disease, or CTAD, conference. He believes the additional Phase 2a clinical data for PTI-125, the company's investigational drug candidate for AD, presented at the meeting were positive and thinks results from the ongoing Phase 2b study in patients with mild-to-moderate AD can be a catalyst for the stock in mid-2020.
SRCI SRC Energy
$3.98

-0.1 (-2.45%)

10/24/19
ROTH
10/24/19
DOWNGRADE
Target $3.55
ROTH
Neutral
SRC Energy downgraded to Neutral from Buy at Roth Capital
Roth Capital analyst John White downgraded SRC Energy to Neutral from Buy with a price target of $3.55, down from $9.00.
11/11/19
RAJA
11/11/19
DOWNGRADE
RAJA
Market Perform
SRC Energy downgraded to Market Perform from Outperform at Raymond James
Raymond James downgraded SRC Energy to Market Perform from Outperform.
08/30/19
LEHM
08/30/19
INITIATION
Target $42
LEHM
Overweight
PDC Energy initiated with an Overweight at Barclays
Barclays analyst William Thompson started PDC Energy (PDCE) with an Overweight rating and $42 price target. The pending merger with SRC Energy (SRCI) creates core Wattenberg critical mass and allows PDC to prioritize free cash flow and return of capital over production growth and Delaware expansion, Thompson tells investors in a research note.
10/24/19
ROTH
10/24/19
DOWNGRADE
Target $3.55
ROTH
Neutral
SRC Energy downgraded to Neutral at Roth Capital
As previously reported, Roth Capital analyst John White downgraded SRC Energy (SRCI) to Neutral from Buy with a price target of $3.55, down from $9. The analyst notes that PDC Energy (PDCE) and SRC Energy had previously announced a definitive merger agreement under which the former will acquire the latter in an all-stock transaction.

TODAY'S FREE FLY STORIES

CEL

Cellcom Israel

$3.18

(0.00%)

16:16
01/19/20
01/19
16:16
01/19/20
16:16
Hot Stocks
Cellcom Israel announces CTO resignation »

Cellcom Israel announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRCA

Verrica Pharmaceuticals

$15.94

0.21 (1.34%)

16:12
01/19/20
01/19
16:12
01/19/20
16:12
Hot Stocks
Verrica announces presentation of data from Phase 3 CAMP trials of VP-102 »

Verrica Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Jul

SO

Southern Company

$67.25

1.08 (1.63%)

, XEL

Xcel Energy

$65.38

0.34 (0.52%)

16:08
01/19/20
01/19
16:08
01/19/20
16:08
Hot Stocks
Southern Power closes sale of Mankato Energy Center to Xcel Energy »

Southern Power, a…

SO

Southern Company

$67.25

1.08 (1.63%)

XEL

Xcel Energy

$65.38

0.34 (0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

LIZI

Lizhi

$11.72

(0.00%)

, DNK

Phoenix Tree

$13.50

(0.00%)

09:10
01/19/20
01/19
09:10
01/19/20
09:10
On The Fly
Opening Day: China's Lizhi, Phoenix Tree flat in trading debut »

Lizhi (LIZI), one of…

LIZI

Lizhi

$11.72

(0.00%)

DNK

Phoenix Tree

$13.50

(0.00%)

VEL

Velocity Financial

$13.58

(0.00%)

IMAB

I-MAB

$12.90

(0.00%)

BSBK

Bogota Financial

$11.70

0.195 (1.70%)

CSPR

Casper Sleep

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLGT

Teligent

$0.40

-0.0025 (-0.62%)

15:53
01/18/20
01/18
15:53
01/18/20
15:53
Conference/Events
Teligent to hold a special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

AYTU

Aytu BioScience

$0.80

0.0014 (0.18%)

15:48
01/18/20
01/18
15:48
01/18/20
15:48
Conference/Events
Aytu BioScience to hold a special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

DVA

DaVita

$79.45

0.43 (0.54%)

15:32
01/18/20
01/18
15:32
01/18/20
15:32
Conference/Events
DaVita to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

TSM

TSMC

$58.58

-0.18 (-0.31%)

09:16
01/18/20
01/18
09:16
01/18/20
09:16
Periodicals
Taiwan tech stocks can ignore China's bluster for now, Barron's says »

China's government…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KKR

KKR

$31.20

0.7 (2.30%)

, APO

Apollo Global

$50.35

1.26 (2.57%)

09:03
01/18/20
01/18
09:03
01/18/20
09:03
Periodicals
KKR undervalued compared with peers, Barron's says »

KKR (KKR) gained 50% last…

KKR

KKR

$31.20

0.7 (2.30%)

APO

Apollo Global

$50.35

1.26 (2.57%)

ARES

Ares Management

$37.29

0.47 (1.28%)

BX

Blackstone

$60.79

0.62 (1.03%)

CG

Carlyle Group

$33.30

0.36 (1.09%)

HLNE

Hamilton Lane

$67.25

-0.02 (-0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

  • 30

    Jan

  • 31

    Jan

  • 31

    Jan

  • 04

    Feb

  • 04

    Feb

  • 05

    Feb

  • 13

    Feb

  • 17

    Feb

  • 26

    Feb

SPCE

Virgin Galactic

$15.65

0.685 (4.58%)

, TWNK

Hostess Brands

$14.03

0.02 (0.14%)

08:56
01/18/20
01/18
08:56
01/18/20
08:56
Periodicals
'Blank-check' companies hot on Wall Street, Barron's says »

More than a quarter of…

SPCE

Virgin Galactic

$15.65

0.685 (4.58%)

TWNK

Hostess Brands

$14.03

0.02 (0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 04

    Mar

GOOG

Alphabet

$1,480.28

28.34 (1.95%)

, NFLX

Netflix

$339.56

0.89 (0.26%)

08:47
01/18/20
01/18
08:47
01/18/20
08:47
Periodicals
Peacock's pricing might be 'killer feature,' Barron's says »

This week, Peacock…

GOOG

Alphabet

$1,480.28

28.34 (1.95%)

NFLX

Netflix

$339.56

0.89 (0.26%)

CMCSK

Comcast

$0.00

(0.00%)

CMCSA

Comcast

$47.48

0.62 (1.32%)

GOOGL

Alphabet Class A

$1,479.12

29.29 (2.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

  • 22

    Jan

  • 23

    Jan

  • 03

    Feb

  • 03

    Feb

  • 10

    Feb

JWN

Nordstrom

$40.34

-0.15 (-0.37%)

, WMT

Walmart

$114.93

-0.96 (-0.83%)

08:36
01/18/20
01/18
08:36
01/18/20
08:36
Periodicals
Casper IPO highlights tech's promise, troubles, Barron' says »

Mattresses have been…

JWN

Nordstrom

$40.34

-0.15 (-0.37%)

WMT

Walmart

$114.93

-0.96 (-0.83%)

CSPR

Casper Sleep

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

  • 18

    Feb

BA

Boeing

$324.11

-7.89 (-2.38%)

, DDAIF

Daimler AG

$0.00

(0.00%)

08:12
01/18/20
01/18
08:12
01/18/20
08:12
On The Fly
Week in Review: How Trump's policies moved stocks »

Catch up on the top…

BA

Boeing

$324.11

-7.89 (-2.38%)

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$13.76

-0.14 (-1.01%)

VWAGY

Volkswagen

$0.00

(0.00%)

FSLR

First Solar

$53.51

-0.42 (-0.78%)

AAPL

Apple

$318.66

3.33 (1.06%)

DQ

Daqo New Energy

$53.61

-0.025 (-0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

  • 29

    Jan

SPOT

Spotify

$148.20

-3.59 (-2.37%)

18:15
01/17/20
01/17
18:15
01/17/20
18:15
Periodicals
Spotify in talks to acquire The Ringer, WSJ reports »

Spotify is in discussions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

CE

Celanese

$117.54

-0.53 (-0.45%)

18:00
01/17/20
01/17
18:00
01/17/20
18:00
Hot Stocks
Celanese announces acetyl intermediates price increases »

Celanese Corporation will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

BYND

Beyond Meat

$109.20

-1.16 (-1.05%)

17:58
01/17/20
01/17
17:58
01/17/20
17:58
Periodicals
Beyond Meat rival gets green light in Canada, The Star says »

Impossible Foods, a maker…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DBD

Diebold

$11.09

-0.49 (-4.23%)

17:42
01/17/20
01/17
17:42
01/17/20
17:42
Periodicals
Breaking Periodicals news story on Diebold »

Diebold Nixdorf divests…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEF

iShares 7-10 Year Treasury Bond ETF

$111.28

-0.13 (-0.12%)

, SHY

iShares 1-3 Year Treasury Bond

$84.73

-0.005 (-0.01%)

17:32
01/17/20
01/17
17:32
01/17/20
17:32
General news
Weekly CFTC Commitment of Traders highlights »

2-YEAR U.S. TREASURY net…

IEF

iShares 7-10 Year Treasury Bond ETF

$111.28

-0.13 (-0.12%)

SHY

iShares 1-3 Year Treasury Bond

$84.73

-0.005 (-0.01%)

SPY

SPDR S&P 500 ETF Trust

$331.98

1.08 (0.33%)

SLV

iShares Silver Trust

$16.82

0.04 (0.24%)

GLD

SPDR Gold Shares

$146.59

0.29 (0.20%)

FXE

Euro Currency Trust

$105.10

-0.43 (-0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UBSFY

Ubisoft

$0.00

(0.00%)

17:32
01/17/20
01/17
17:32
01/17/20
17:32
Periodicals
Ubisoft to restructure editorial team after difficult 2019, VGC reports »

Ubisoft intends to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 18

    Feb

IMVT

Immunovant

$17.04

-0.01 (-0.06%)

17:27
01/17/20
01/17
17:27
01/17/20
17:27
Syndicate
Breaking Syndicate news story on Immunovant »

Immunovant files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TBLT

ToughBuilt

$0.33

-0.0255 (-7.11%)

17:20
01/17/20
01/17
17:20
01/17/20
17:20
Syndicate
ToughBuilt files to sell common stock, no amount given »

Maxim acted as sole book…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYO

Myomo

$0.32

0.0062 (1.98%)

17:18
01/17/20
01/17
17:18
01/17/20
17:18
Conference/Events
Myomo to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

SRRA

Sierra Oncology

$0.40

-0.02 (-4.76%)

17:14
01/17/20
01/17
17:14
01/17/20
17:14
Conference/Events
Sierra Oncology to host virtual special shareholder meeting »

Virtual Special…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

SRNE

Sorrento Therapeutics

$4.26

-0.15 (-3.40%)

17:10
01/17/20
01/17
17:10
01/17/20
17:10
Syndicate
Breaking Syndicate news story on Sorrento Therapeutics »

Sorrento Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKER

Akers Biosciences

$3.45

-0.1 (-2.82%)

17:01
01/17/20
01/17
17:01
01/17/20
17:01
Hot Stocks
Akers Biosciences reaches settlement agreements on two derivative actions »

Akers Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.